IFNA1 and neoplasm: VSV is naturally oncolytic in IFN-defective tumor cells, can be attenuated (e.g., VSV-IFNβ), and is being evaluated clinically as VSV-glycoprotein (GP)—(pseudotyped with lymphocytic choriomeningitis virus (LCMV) GP) and VSV-human Monocyte Chemoattractant Protein 3 (hMCP3) to reduce neurotropism and the ability to stimulate a host immune response against infected cells [68,69] (Table 2).